Congratulations | Huayi Pharma Being One of the “Top 20 Chinese CDMO Enterprises” for Six Consecutive Years

The 2024 International Pharmaceutical Services Industry Innovation and Development Forum and 9^th PDI China submit opened in the morning of July 4, 2024. This summit focused on gathering innovative elements, bringing together the wisdom of experts in the innovative drug industry, and building a platform for the exchange of cutting-edge academic ideas in innovative drugs. The summit aimed to jointly explore the development trends of innovative drugs, innovation in the biopharmaceutical industry chain, cutting-edge technologies, clinical trials, and the core commercial value of innovative drug enterprises etc. to effectively promote the creation of a pharmaceutical innovation ecosystem and new quality productivity and accelerate the high-quality development of China’s innovative drug industry.

At the banquet, the highly anticipated “China Pharmaceutical Drug R&D Strength Ranking” was announced. Huayi Pharmaceuticals (Anhui) Co., Ltd. stood out from hundreds of pharmaceutical enterprises and was awarded the title of “Top 20 Chinese CDMO Enterprises”. This is the sixth consecutive year that our company has ranked among the top in this list!

This honor is also the recognition of Huayi Pharma’s position and strength in the professional field. We will continue to uphold the corporate value of “create value and benefit for the world” and provide better services to MAH in the formulation CDMO field. We insist on the principle of “making high quality drugs at affordable cost” and look forward to working hand in hand with our pharmaceutical colleagues to create a brilliant future together!